Bayer HealthCare has decided to end three ongoing clinical studies investigating the safety and efficacy of Trasylol on transfusion requirements and blood loss in adults undergoing elective spinal fusion surgery, pneumonectomy or esophagectomy for cancer, and radical or total cystectomy in bladder cancer.Trasylol should be administered only in surgical settings where cardiopulmonary bypass can be rapidly initiated. Bayer's decision to discontinue these trials was not made based on any safety findings On November 18, 2006 an independent Data Monitoring Committee reviewed safety data on these three studies, examining data for the first random 120 patients.
Trasylol is the only drug approved by the FDA and several other regulatory authorities to reduce blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery in patients who are at an increased risk for blood loss and blood transfusion.
If you or a loved one has suffered kidney failure, stroke, or heart attack as a result of the hospital using Trasylol during CABG, you need to talk to a law firm that specializes in unsafe drugs and product negligence lawsuits. Please contact us so we can discuss the facts.
source: http://www.medicalnewstoday.com/medicalnews.php?newsid=61663
